You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Microbiotica, Cambridge University, and Cancer Research UK will develop microbiome co-therapeutics and gut bacteria signatures for predicting immunotherapy response.
A Broad Institute-led team found that differences by ancestry could affect not only how cancer develops but also treatment approaches.
Integrated analyses uncovered recurrent changes in renal medullary carcinoma, including potential treatment vulnerabilities stemming from DNA replication stress.
WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.
Three new studies have found that the presence of B cells in tertiary lymphoid structures in tumors is associated with a favorable response to immunotherapy.
In an AMP Global presentation, Danish Cancer Society Research Center scientists used the test to study urine samples from individuals who developed bladder cancer up to 15 years later.
In Genome Biology this week: variants linked to disorders of sex development, new candidate genes for ciliopathies, and more.
A Baylor College of Medicine-led team uncovered nine genomic subtypes of kidney cancer that may help direct patients' treatments.
In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.
Paradigm will use its NGS-based PCDx panel to characterize patient tissue samples in a phase I clinical study of altiratinib.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.